Lonza Group

Last updated
Lonza Group AG
Company type Aktiengesellschaft
SIX:  LONN
SGX: O6Z
SMI component
ISIN CH0013841017  OOjs UI icon edit-ltr-progressive.svg
Industry Pharmaceuticals
biotechnology
Founded1897
Headquarters Basel, Switzerland
Key people
Albert M. Baehny (Ad-interim CEO)
Products Biopharmaceuticals
Revenue CHF 4.508 billion (2021) [1]
CHF 1.665 billion (2021) [1]
Total assets CHF 16.459 billion (end 2021) [1]
Total equity CHF 9.823 billion (end 2021) [1]
Number of employees
17,500 (2023)
Website www.lonza.com

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

Contents

History

Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. In the course of the 20th century Lonza evolved from hydroelectricity and C2 chemistry, through nitrogen chemistry to petrochemistry before moving into fine chemistry and biochemistry. [2]

Initially, the company produced electricity. The following year, calcium carbide manufacture began using the electricity to heat a furnace to the 2000 °C required for quicklime to react with coal. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909. Competition from electric lighting reduced demand for calcium carbide and in 1915 Lonza started industrial production of calcium cyanamide which became popular as a cheap nitrogenous fertilisers, only to be supplanted by urea. Several new processes were launched in the 1920s. In addition to an electrolysis plant capable of making 5800 m3 hydrogen per hour, came metaldehyde, ammonia and ketene. In 1923, Lonza started to convert calcium carbide to metaldehyde (sold as a solid fuel under the brand 'Meta' and then slug repellant) via acetylene and acetaldehyde. In 1925, ammonia production was started, with a process licensed from Casale. Ammonia was also converted to nitric acid. With calcium cyanamide and calcium nitrate (made from nitric acid), Lonza commercialised formulated fertilisers starting in the 1930s. At the start of World War II, Lonza was contracted by the Swiss government to produce synthetic fuel, which it did by converting acetaldehyde to paraldehyde, used as an additive in transport fuel. In 1928, ketene production started using acetic acid made by oxidation of acetaldehyde. Ketene was initially used to make cellulose acetate for rayon manufacture, but after 1947 Lonza converted most of its ketene to diketene, which was then converted to a range of chemical precursors. Diketene capacity rose to 18'000t per year in 1993. In 1956, the production of niacin (an important vitamin) via 5-ethyl-2-methyl-pyridine. In the 1940s, Lonza used its C2 basis to enter the vinyl chloride business. The production was relocated to Sins and finally discontinued.

At the 1959 AGM, it was decided to back integrate into petrochemistry, and Montecatini was contracted to build the world's smallest cracker in Visp. The initial failure of this plant to meet its specifications triggered a CHF12mio penalty, which Lonza used to build a research center.

Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs. Lonza also manufactures Imbruvica for Pharmacyclics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and Sanofi partnered to construct a new facility for production of biologics. [14]

In May 2020, Moderna struck a manufacturing deal with Lonza to produce its (mRNA-1273) COVID-19 vaccine active ingredient while expanding sterile production and fill-finish activities to 500 million doses starting in 2021. [15] Production of the mRNA bulk vaccine started in January 2021, soon after an official visit by Swiss Federal Councilor Alain Berset. Lonza Group is responsible for the global production of two-thirds of the raw materials for the Moderna vaccine at combined U.S. and Swiss facilities. The company also started to collaborate with Altimmune Inc. for the development of a nasal COVID-19 vaccine. [16] [17]

Corporate structure

As of 2020, Lonza's business areas include:

In November 2019, Chairman Albert Baehny became both chairman and interim CEO of Lonza after chief executive officer (CEO) Marc Funk left after 9 months. [18] In November 2020, Pierre-Alain Ruffieux commenced his role as Chief Executive Officer [19] which ended at the end of September 2023, totaling 2 years and 11 months in the position of CEO. Chairman Albert Baehny became again, both chairman and interim CEO, as from October 2023. [20]

Business operations

As of 2018, Lonza had twenty-four self-described major sites located in the United States, India, the Czech Republic, Belgium, Spain, China, France, South Africa, Switzerland, Singapore, Mexico, Japan, Brazil and the United Kingdom. [21] This site accounting shows significant changes from a 2016 self-description, which listed sixteen major sites. [22] The presence in India was established in Genome Valley, where ground was broken in 2011. [23] [24] [25]

In 2018, Lonza opened a 300,000 square feet (28,000 m2) facility in the United States in Pearland, Texas (a suburb of Houston). [26] This is one of four sites which are focused on cell and gene therapy, the other three being in Portsmouth, New Hampshire; Geleen, Netherlands; and Singapore. [26]

As of 2023, the company has employed over 17,500 people, across about 35 countries. [27] [28]

Related Research Articles

FUJIFILM Diosynth Biotechnologies, abbreviated FDB and also referred to simply as Diosynth, is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies. FUJIFILM Diosynth Biotechnologies is the world's second largest contract manufacturer of biopharmaceuticals, with manufacturing facilities in Morrisville, North Carolina and College Station, Texas in the United States, Teesside, United Kingdom and Hillerød, Denmark in Europe, and recently added sites in Thousand Oaks, California and Watertown, Massachusetts. FUJIFILM Diosynth Biotechnologies operates a highly automated multipurpose manufacturing facility in College Station, Texas under the federal government's Center for Innovation in Advanced Development and Manufacturing (CIADM) program, which is the largest scale-out cell culture manufacturing facility in the United States.

<span class="mw-page-title-main">DSM (company)</span> Dutch multinational corporation

Koninklijke DSM N.V., was a Dutch multinational corporation active in the fields of health, nutrition and materials. Headquartered in Heerlen, at the end of 2017 DSM employed 21,054 people in approximately 50 countries and posted net sales of €8.632 billion in 2018 and €9.204 billion in 2021. In May 2023 it merged with the Swiss company Firmenich to form a new entity named DSM-Firmenich.

Visp is the capital of the district of Visp in the canton of Valais in Switzerland.

<span class="mw-page-title-main">Ion-exchange resin</span> Organic polymer matrix bearing ion-exchange functional groups

An ion-exchange resin or ion-exchange polymer is a resin or polymer that acts as a medium for ion exchange. It is an insoluble matrix normally in the form of small microbeads, usually white or yellowish, fabricated from an organic polymer substrate. The beads are typically porous, providing a large surface area on and inside them where the trapping of ions occurs along with the accompanying release of other ions, and thus the process is called ion exchange. There are multiple types of ion-exchange resin. Most commercial resins are made of polystyrene sulfonate, followed up by polyacrylate.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Borregaard</span>

Borregaard is a Norwegian company, established in 1889 in the southeastern town of Sarpsborg in Østfold county. Its main products were traditionally pulp and paper. The company later started producing chemicals based on timber as a raw material. After a takeover in 1986, Borregaard was part of the chemical division of the Orkla Group until it was spun off and introduced to the Oslo Stock Exchange in October 2012. It had 1050 employees in 2016.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Johnson & Johnson Innovative Medicine is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

<span class="mw-page-title-main">Fine chemical</span> Pure chemical substances produced by and for the chemical industry

In chemistry, fine chemicals are complex, single, pure chemical substances, produced in limited quantities in multipurpose plants by multistep batch chemical or biotechnological processes. They are described by exacting specifications, used for further processing within the chemical industry and sold for more than $10/kg. The class of fine chemicals is subdivided either on the basis of the added value, or the type of business transaction, namely standard or exclusive products.

<span class="mw-page-title-main">Patheon</span>

Patheon is a service brand within Thermo Fisher Scientific’s brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

Repros Therapeutics Inc. (Nasdaq: RPRX), was a US-based development stage biopharmaceutical company headquartered in The Woodlands, Texas. Founded in 1987 as Zonagen, it focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski was the CEO of this company.

<span class="mw-page-title-main">Sumitomo Chemical</span> Major Japanese chemical company

Sumitomo Chemical Co., Ltd. is a major Japanese chemical company. The company is listed on the first section of the Tokyo Stock Exchange and is a constituent of the on the Nikkei 225 stock index. It's a member of the Sumitomo group and was founded in 1913 as a fertilizer manufacturing plant.

Eurogentec is an international biotechnology supplier, based in Belgium, that specializes in genomics and proteomics kits and reagents as well as cGMP biologics. The company was founded in 1985 as a spin-off from the University of Liège. Eurogentec's contract manufacturing organization facilities are licensed by the Belgian Ministry of Health to produce clinical trial and commercial biopharmaceutical material and also licensed by the US FDA to manufacture a commercial recombinant protein product for the US market. Eurogentec operates two manufacturing facilities in Belgium that provide custom biologics and oligonucleotide-based components for diagnostic and therapeutic/prophylactic applications.

Teva API is an international pharmaceutical company headquartered in Israel. Teva API is a stand-alone business unit of Teva Pharmaceutical Industries limited, the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.

Dishman Carbogen Amcis Ltd is an Indian multinational pharmaceutical company specialized in the manufacture of active ingredients and contract development and manufacturing. Dishman employs over 1,000 people worldwide and is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).

<span class="mw-page-title-main">Pharmaceutical industry in Switzerland</span> Overview of the pharmaceutical industry in Switzerland

The pharmaceutical industry in Switzerland directly and indirectly employs about 135,000 people. It contributes 5.7% of the gross domestic product of Switzerland and 30% of the country's exports. In 2017 about 30% of Swiss exports were chemical products. In the same year Switzerland was the second largest exporter of packaged medicine in the world, with about 11% of the global total, worth $36.5 billion.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

<span class="mw-page-title-main">Moderna COVID-19 vaccine</span> RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered in two or three 0.5-mL doses given by intramuscular injection at an interval of at least 28 days apart.

<span class="mw-page-title-main">Moncef Slaoui</span> Moroccan-American-Belgian doctor and researcher

Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Switzerland</span> Plan to immunize against COVID-19

COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

References

  1. 1 2 3 4 "Annual Results 2021" (PDF).
  2. ↑ Eschenmooser, Walter (June 1997). "100 Years of Progress with LONZA". CHIMIA. 51 (6): 259–269. doi: 10.2533/chimia.1997.259 . S2CID   100485418.
  3. ↑ "Lonza expands into Singapore". icis.com. Independent Commodity Intelligence Services. 12 Jan 1996. Retrieved 8 October 2020.
  4. ↑ "Lonza Group Ltd". Encyclopedia. Retrieved 21 September 2020.
  5. ↑ "2005: Niepolomice site". Polynt Group. Retrieved 9 October 2020.
  6. ↑ "2006: Polynt S.p.A." Polynt Group. Retrieved 9 October 2020.
  7. ↑ "Lonza sells Singapore PIA plant to Perstorp". Dr. Gupta Verlag. 10 October 2007. Retrieved 8 October 2020.
  8. ↑ Simonian, Haig (11 July 2011). "Lonza in $1.4bn acquisition of Arch Chemicals". Financial Times . Retrieved 13 November 2011.
  9. ↑ "Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals" (Press release). Lonza. 15 August 2016. Retrieved 2018-04-15.[ self-published source ]
  10. ↑ "Lonza Buys Capsugel for $5.5B Cash". Genetic Engineering & Biotechnology News. 15 December 2016. Retrieved 2018-04-15.
  11. ↑ Lonza und Sanofi bauen gemeinsame Fabrik im Wallis. Telebasel, February 27, 2017
  12. ↑ "AR2021". Lonza.com.
  13. ↑ "Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn - Pharmafile". pharmafile.com. 2024-03-20. Retrieved 2024-03-20.
  14. ↑ "Company History". Company Profile. Retrieved 2018-04-15.[ self-published source ]
  15. ↑ Taylor, N. (Aug. 2020). Moderna scaling up ex-US COVID-19 vaccine capacity as EU deal nears. BioPharma-Reporter.com. Retrieved 23 September 2020.
  16. ↑ "Lonza plant in Switzerland starts making ingredients for Moderna COVID shot". Reuters. Retrieved 15 March 2021.
  17. ↑ "Lonza collabore avec Altimmune pour développer son vaccin nasal"(in french). Tribune de Genève. Retrieved 15 March 2021.
  18. ↑ "Lonza leader Marc Funk quits after just 9 months as CEO". FiercePharma.
  19. ↑ "Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux". Lonza.com.
  20. ↑ "Ad Hoc announcement pursuant to Art. 53 LR". 18 September 2023. Retrieved 20 September 2023.
  21. ↑ "Fact Sheet". Company Profile. Lonza. Retrieved 2018-04-15.[ self-published source ]
  22. ↑ "Facts". Company Profile. Lonza. Archived from the original on 10 October 2016. Retrieved 2018-04-15.[ self-published source ]
  23. ↑ "Lonza to invest Rs 250 cr in Genome Valley". Business Standard. India. 25 September 2010. Retrieved 2018-04-15.
  24. ↑ "Lonza Group to set up a bio pharma unit at Genome Valley". ibis. Retrieved 2018-04-15.
  25. ↑ "Lonza provisionally allotted 30 Acres of land in the "Genome Valley", Hyderabad (India)" (Press release). Lonza. 29 May 2009.[ self-published source ]
  26. 1 2 Philippidis, Alex (10 April 2018). "Lonza Opens Cell and Gene Therapy Facility in Pearland, TX". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2018-04-15.
  27. ↑ "About Us". Lonza. Retrieved February 6, 2023.
  28. ↑ "Lonza Number of Employees". Macroaxis. Retrieved February 6, 2023.

Commons-logo.svg Media related to Lonza Group at Wikimedia Commons

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.